Announcements Trials
Browse Landscape

Phase

Phase 1/2 3

Status

Completed 12Active not recruiting 5Terminated 3Recruiting 2

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3Myeloid 2

Conditions

Multiple Myeloma 10Burkitt Lymphoma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Vomiting 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Nausea 2Smoldering Multiple Myeloma 1Renal Insufficiency 1Prostatic Neoplasms 1Plasmacytoma 1Ovarian Neoplasms 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hematologic Neoplasms 1Gastrointestinal Neoplasms 1Fallopian Tube Neoplasms 1Brenner Tumor 1Blast Crisis 1

Interventions

Cyclophosphamide 48Methotrexate 33Cytarabine 27fludarabine 23fludarabine phosphate 22Rituximab 22Filgrastim 21Vincristine 19Busulfan 19Whole-Body Irradiation 18Mycophenolic Acid 18Dexamethasone 18Antilymphocyte Serum 17Cyclosporine 16Etoposide 15Tacrolimus 14Melphalan 14Calcium Dobesilate 14pegaspargase 12Peripheral Blood Stem Cell Transplantation 12Doxorubicin 12Radiotherapy 11Clofarabine 11Granulocyte Colony-Stimulating Factor 10Thiotepa 9Bortezomib 9thymoglobulin 8Dasatinib 8Asparaginase 8plerixafor 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Precursor Cell Lymphoblastic Leukemia-Lymphoma × auricularum × Clear all
NCT05032183 2025-08-11

Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

M.D. Anderson Cancer Center

Phase 1/2 Terminated
4 enrolled 8 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04752163 2025-05-23

DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Terminated
17 enrolled 15 charts
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03576547 2025-05-08

Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Terminated
9 enrolled 11 charts
LymphoidMyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡